Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orthocell Ltd ( (AU:OCC) ) just unveiled an update.
Orthocell Ltd has announced the quotation of 22,846,154 new ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 24, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s capital structure and market presence, which could have significant implications for its stakeholders and industry positioning.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a company operating in the biotechnology industry, focusing on developing and commercializing regenerative medicine products. The company is primarily involved in creating innovative solutions for soft tissue injuries and musculoskeletal conditions, aiming to improve patient outcomes in these areas.
Average Trading Volume: 628,709
Technical Sentiment Signal: Buy
Current Market Cap: A$323.7M
See more insights into OCC stock on TipRanks’ Stock Analysis page.